Key result
Olmesartan displayed a higher degree of insurmountability and a slower dissociation half-life (72 minutes) from the human AT1 receptor compared to telmisartan (29 minutes).
Olmesartan displays a higher degree of insurmountability, slower dissociation, and higher affinity for the AT1 receptor compared to telmisartan in vitro.
May favor olmesartan for sustained AT1 blockade; hypothesis-generating for ARB selection, needs clinical outcome trials.
BACKGROUND AND PURPOSE: Whereas some angiotensin II (Ang II) type 1 receptor blockers (ARBs) produce surmountable antagonism of AT(1) receptors, others such as olmesartan and telmisartan display varying degrees of insurmountability. This study compared the molecular interactions of olmesartan and telmisartan with the human AT(1) receptor, using well characterised in vitro methods and model systems. EXPERIMENTAL APPROACH: CHO-K1 cells that stably express human AT(1) receptors (CHO-hAT(1) cells) were used in several pharmacological studies of olmesartan and telmisartan, including direct radioligand binding and inhibition of Ang II-induced inositol phosphate (IP) accumulation. KEY RESULTS: Both ARBs were found to be competitive antagonists that displayed high affinity, slow dissociation, and a high degree of insurmountability for the AT(1) receptor (the latter greater with olmesartan). Their receptor interactions could be described by a two-step process with the initial formation of a loose complex (IR) and subsequent transformation into a tight binding complex (IR*). In washout experiments, [(3)H] telmisartan dissociated from the receptor with a half-life of 29 min and the Ang II-mediated IP accumulation response was 50% maximally restored within 24 min, whereas values for [(3)H] olmesartan were 72 min and 76 min, respectively. CONCLUSIONS AND IMPLICATIONS: The high degree of insurmountability, slow dissociation, and high affinity of olmesartan for its receptor may relate to its ability to stabilise IR* via the carboxyl group of its imidazole core. In comparison, telmisartan displays a less potent interaction with the receptor.
No takes yet. Share an insight, caveat, or question.
Lê et al. (2007) studied this question. Olmesartan vs. Telmisartan was evaluated on Dissociation half-life from AT1 receptor (minutes). Olmesartan displayed a higher degree of insurmountability and a slower dissociation half-life (72 minutes) from the human AT1 receptor compared to telmisartan (29 minutes).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: